Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation

Front Immunol. 2021 Feb 24:12:641910. doi: 10.3389/fimmu.2021.641910. eCollection 2021.

Abstract

Histone deacetylase inhibitors are currently the most studied drugs because of their beneficial effects on inflammatory response. Emerging data from numerous basic studies and clinical trials have shown that histone deacetylase inhibitors can suppress immune-mediated diseases, such as graft-vs.-host disease (GVHD), while retaining beneficial graft-vs.-leukemia (GVL) effects. These drugs prevent and/or treat GVHD by modifying gene expression and inhibiting the production of proinflammatory cytokines, regulating the function of alloreactive T cells, and upregulating the function and number of regulatory T cells. Some of these drugs may become new immunotherapies for GVHD and other immune diseases.

Keywords: allo-reactive T cells; allogeneic hematopoietic stem cell transplantation; epigenetic regulation; graft-vs.-host disease; histone deacetylase inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allografts
  • Graft vs Host Disease* / immunology
  • Graft vs Host Disease* / pathology
  • Graft vs Host Disease* / prevention & control
  • Graft vs Leukemia Effect* / drug effects
  • Graft vs Leukemia Effect* / immunology
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Stem Cell Transplantation*
  • T-Lymphocytes, Regulatory / immunology*

Substances

  • Histone Deacetylase Inhibitors
  • Immunologic Factors